The "Urethral Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players" report has been added to ResearchAndMarkets.com's offering.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Urethral Cancer
- The pipeline guide reviews pipeline therapeutics for Urethral Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration until discovery and undisclosed stages
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities
- The pipeline guide reviews key companies involved in Urethral Cancer therapeutics and enlists all their major and minor projects
- The pipeline guide evaluates Urethral Cancer therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects
- The pipeline guide reviews latest news related to pipeline therapeutics for Urethral Cancer
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Find and recognize significant and varied types of therapeutics under development for Urethral Cancer
- Classify potential new clients or partners in the target demographic
- Develop tactical initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics
- Formulate corrective measures for pipeline projects by understanding Urethral Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline
Key Topics Covered:
Introduction
- Report Coverage
- Overview
Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
Companies Involved in Therapeutics Development
Drug Profiles
For more information about this report visit https://www.researchandmarkets.com/r/oi7p7i
View source version on businesswire.com: https://www.businesswire.com/news/home/20220624005374/en/
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900